Related Experiment Video
Updated: Aug 5, 2025

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
Published on: July 8, 2025
A Molecular Docking Study Reveals That Short Peptides Induce Conformational Changes in the Structure of Human Tubulin
Oluwakemi Ebenezer1,2, Nkululeko Damoyi1, Michael Shapi1
1Department of Chemistry, Faculty of Natural Science, Mangosuthu University of Technology, Umlazi 4031, South Africa.
Abstract:
Microtubules are cylindrical protein polymers assembled in the cytoplasm of all eukaryotic cells by polymerization of aβ tubulin dimers, which are involved in cell division, migration, signaling, and intracellular traffic. These functions make them essential in the proliferation of cancerous cells and metastases. Tubulin has been the molecular target of many anticancer drugs because of its crucial role in the cell proliferation process. By developing drug resistance, tumor cells severely limit the successful outcomes of cancer chemotherapy. Hence, overcoming drug resistance motivates the design of new anticancer therapeutics. Here, we retrieve short peptides obtained from the data repository of antimicrobial peptides (DRAMP) and report on the computational screening of their predicted tertiary structures for the ability to inhibit tubulin polymerization using multiple combinatorial docking programs, namely PATCHDOCK, FIREDOCK, and ClusPro. The interaction visualizations show that all the best peptides from the docking analysis bind to the interface residues of the tubulin isoforms αβl, αβll, αβlll, and αβlV, respectively. The docking studies were further confirmed by a molecular dynamics simulation, in which the computed root-mean-square deviation (RMSD), and root-mean-square fluctuation (RMSF), verified the stable nature of the peptide-tubulin complexes. Physiochemical toxicity and allergenicity studies were also performed. This present study suggests that these identified anticancer peptide molecules might destabilize the tubulin polymerization process and hence can be suitable candidates for novel drug development. It is concluded that wet-lab experiments are needed to validate these findings.
Insights
Computational screening identified short peptides that inhibit tubulin polymerization, offering potential new anticancer drugs to overcome chemotherapy resistance. Further research is needed for validation.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Microtubules, formed by αβ tubulin dimers, are crucial for cell division and proliferation, making them key targets for anticancer drugs.
- Tumor cells often develop drug resistance, limiting the effectiveness of current chemotherapy and necessitating the development of novel therapeutics.
Purpose of the Study:
- To computationally screen antimicrobial peptides for their potential to inhibit tubulin polymerization.
- To identify novel peptide candidates for anticancer drug development that can overcome drug resistance.
Main Methods:
- Retrieved short peptides from the Antimicrobial Peptide Database (DRAMP).
- Utilized multiple docking programs (PATCHDOCK, FIREDOCK, ClusPro) to predict tertiary structures and binding affinities.
- Performed molecular dynamics simulations to confirm the stability of peptide-tubulin complexes.
- Conducted physiochemical toxicity and allergenicity assessments.
Main Results:
- Docking analysis revealed that selected peptides bind to the interface residues of tubulin isoforms (αβI, αβII, αβIII, αβIV).
- Molecular dynamics simulations confirmed stable interactions between the identified peptides and tubulin.
- Toxicity and allergenicity studies provided initial safety assessments for the candidate peptides.
Conclusions:
- The identified peptides show potential to destabilize tubulin polymerization, suggesting their utility as novel anticancer agents.
- These peptides represent promising candidates for further development into drugs to combat cancer, particularly in cases of drug resistance.
- Experimental validation is required to confirm the therapeutic efficacy of these peptide candidates.
More Related Videos
06:30Author Spotlight: Purifying High-Quality Tubulin to Study Protein Dynamics and Therapeutic Applications
Published on: October 11, 2024
07:54Purification of Tubulin with Controlled Posttranslational Modifications and Isotypes from Limited Sources by Polymerization-Depolymerization Cycles
Published on: November 5, 2020